The notices it replaced
- Reissues: PAR-23-219 SBIR/STTR Commercialization Readiness Pilot (CRP) Program Technical Assistance and Late Stage Development (SB1, Clinical Trial Not Allowed)
- 2 steps back: PAR-20-129 SBIR/STTR Commercialization Readiness Pilot (CRP) Program Technical Assistance and Late Stage Development (SB1, Clinical Trial Not Allowed)
- 3 steps back: PAR-19-333 SBIR/STTR Commercialization Readiness Pilot (CRP) Program Technical Assistance and Late Stage Development (SB1, R44) Clinical Trial Not Allowed
- 4 steps back: PAR-16-027 SBIR/STTR Commercialization Readiness Pilot (CRP) Program: Technical Assistance and Late Stage Development (SB1)
Who won it before
141 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $124,088,739 in first-year total cost, median $954,824.
Most frequent study sections
- Special Emphasis Panel[ZRG1 ETTN-C (56)]36
- Special Emphasis Panel[ZRG1 MCST-B (19)]35
- Special Emphasis Panel[ZRG1 IMST-K (19)]29
- Special Emphasis Panel[ZRG1 MCST-K (19)]14
- Special Emphasis Panel[ZRG1 IMST-H (15)]5
Most frequent institutions
- SANARIA, INC.4
- CYTEX THERAPEUTICS INC.3
- HELIXBIND, INC.3
- TURING MEDICAL TECHNOLOGIES INC3
- BIOSENSICS, LLC2
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2025 | CRP: Noninvasive brain stimulation for chronic pain treatment1SB1AG091887-01 · under PAR-23-219 | DIPIETRO, LAURAWAGNER, TIMOTHY ANDREW | HIGHLAND INSTRUMENTS, INC., MA | $2,055,669 | ZRG1 |
| 2025 | Novel, Non-hormonal Therapeutic for Endometriosis1SB1HD118921-01 · under PAR-23-219 | PETROSSIAN, TANYA CHRISTINEH | ENDOMET BIOSCIENCES, INC, CA | $2,045,782 | ZRG1 |
| 2025 | Preclinical Characterization of CRAC Channel Inhibitors for the Treatment of Alzheimer's Disease1SB1AG087756-01A1 · under PAR-23-219 | GREENBERG, MILTON L | VIVREON BIOSCIENCES, LLC, CA | $1,996,385 | ZRG1 |
| 2025 | Achieving FDA Approval & Commercial Readiness for Beacon-AUD: A Digital Diagnostic Medical Device for Alcohol Use Disorder1SB1AA032146-01 · under PAR-23-219 | SNIDER, SARAH EMILY | BEAM DIAGNOSTICS, INC., VA | $1,651,213 | ZRG1 |
| 2025 | Commercialization Readiness for a Portable PET Insert System for Simultaneous TOF-PET and MR Brain Imaging1SB1MH139143-01 · under PAR-23-219 | CHANG, CHENMING | PETCOIL, INC., CA | $1,596,935 | ZRG1 |
| 2025 | A Centralized Clinical Research Tool for Accelerating the Development, Evaluation, and Dissemination of Expert-Developed, Evidence-Based, and AI-Enhanced Digital Mental Health Therapies1SB1MH142181-01 · under PAR-23-219 | AHLE, MATTHEW WILLIAMCOMER, JONATHAN STIMMONS, ADELA | COLLIGA APPS CORP., TX | $1,444,181 | ZMH1 |
| 2025 | Commercialization Readiness Pilot for A Comprehensive Platform for Pediatric Cranial Evaluation1SB1DE034606-01A1 · under PAR-23-219 | SEIFABADI, REZA | PEDIAMETRIX INC., MD | $1,000,000 | ZRG1 |
| 2025 | Compensation-Free Flow Cytometer with Expanded Reagent Choices and Reduced Manufacturing Costs1SB1GM157775-01A1 · under PAR-23-219 | VACCA, GIACOMO | KINETIC RIVER CORPORATION, CA | $999,998 | ZGM1 |
| 2025 | A Point of Care Urine Test to Aid Diagnosis of Aspergillosis1SB1AI186689-01A1 · under PAR-23-219 | DAVENPORT, DEWAYNEMARR, KIEREN A. | PEARL DIAGNOSTICS, INC., MD | $999,316 | ZRG1 |
| 2025 | Development of highly potent human monoclonal for RSV immunoprophylaxis1SB1AI191871-01A1 · under PAR-23-219 | MONSON, ELLENZEITLIN, LARRY | MAPP BIOPHARMACEUTICAL, INC., CA | $993,353 | ZAI1 |
| 2025 | Bloodstream infection detection directly on whole blood1SB1AI192001-01A1 · under PAR-23-219 | CELEDON, ALFREDO ANDRES | SCANOGEN, INC., MD | $969,449 | ZAI1 |
| 2025 | RetiVue EntireEye - A Handheld, High-Resolution, Non-Contact, One Image, Widefield Retinal Screening Camera for Premature and Healthy Newborn Babies1SB1EY037120-01 · under PAR-23-219 | JUN, ALBERT SYATES, PAUL A. | RETIVUE, VA | $745,607 | ZRG1 |
| 2025 | 3D-printed Skin and Bone Integrated Pylon (SBIP-3D) for Direct Skeletal Attachment of Limb Prostheses.1SB1AR086711-01 · under PAR-23-219 | PITKIN, MARK | POLY-ORTH INTERNATIONAL, MA | $594,000 | ZAR1 |
| 2025 | Readying the commercialization of Omega device as an improved safe and efficacious treatment for drug-failed GERD patients1SB1DK143853-01 · under PAR-23-219 | TIHON, CLAUDE NMN | APLOS MEDICAL INC, MN | $570,706 | ZRG1 |
| 2025 | Commercialization Readiness Pilot Program support for: HATS-OFF1SB1HL180153-01 · under PAR-23-219 | KALE, KAUSTUBH | AVENTUSOFT, LLC, FL | $500,000 | ZRG1 |
| 2025 | Integration of Sotair with Capnography for Standardizing Manual Ventilation Technique and Improving Patient Outcomes1SB1HL182470-01 · under PAR-23-219 | PRABHUDESAI, PRATHAMESH P | SAFEBVM CORP., MA | $499,932 | ZHL1 |
| 2025 | Advancing manufacturing and release testing of a gene editing therapy for Duchenne muscular dystrophy1SB1AR084953-01A1 · under PAR-23-219 | YOUNG, COURTNEY S | MYOGENE BIO, LLC, CA | $499,300 | ZRG1 |
| 2025 | Commercialization of the Head Up CPR System for Improving Survival after Cardiac Arrest1SB1HL182469-01 · under PAR-23-219 | LURIE, KEITH | RESUSCITATION INNOVATIONS LLC, MN | $498,453 | ZHL1 |
| 2025 | Commercialization Readiness Pilot for Flow Acceleration for Stroke Thrombolysis (FAST) System1SB1NS139910-01A1 · under PAR-23-219 | CREIGHTON, FRANCIS MILTON | UNANDUP, LLC, MO | $299,982 | ZRG1 |
| 2025 | Preparing IND filing for novel lung cancer therapeutic1SB1CA301959-01A1 · under PAR-23-219 | BEVERLIN II, BRYCE | QUENCH MEDICAL, INC., MN | $249,815 | ZCA1 |
| 2025 | Development of drug product to support a Phase 0/1b dose escalation trial of MT-125 in recurrent high grade gliomas1SB1CA302068-01 · under PAR-23-219 | BROWNSTEIN, MICHAEL J | MYOSIN THERAPEUTICS INC., FL | $249,417 | ZRG1 |
| 2024 | Manufacture of an intracerebroventricular Enzyme Replacement Therapy for CLN1 Batten Disease1SB1NS135733-01 · under PAR-20-129 | EKINS, SEAN | COLLABORATIONS PHARMACEUTICALS, INC., NC | $1,840,246 | ZRG1 |
| 2024 | Ryan® CompanionBot for Assisting Older Adults with Early-Stage Alzheimer's Disease and Dementia1SB1AG087755-01 · under PAR-23-219 | MAHOOR, MOHAMMAD | DREAM FACE TECHNOLOGIES, LLC, CO | $1,424,731 | ZRG1 |
| 2024 | Commercialization readiness of motion-robust brain MRI for pediatric healthcare1SB1MH135555-01 · under PAR-20-129 | BERTOLERO, MAXWELLBRUENER, KEN | TURING MEDICAL TECHNOLOGIES INC, MO | $1,325,626 | ZRG1 |
| 2024 | Commercialization Readiness of Wearable Optically Pumped Magnetoencephalography1SB1MH136846-01 · under PAR-23-219 | SHAH, VISHAL K | QUSPIN, CO | $1,315,183 | ZRG1 |
| 2024 | Adding technology that will enhance commercialization of our neuroscience-based innovative assistive technology platform for living with Alzheimer's disease and Alzheimer's disease related dementia1SB1AG087924-01 · under PAR-23-219 | GOLDEN, MATTHEW | MAPHABIT, INC., GA | $1,246,208 | ZRG1 |
| 2024 | Initiation of ARN-75039 API and Drug Product NDA Registration Path and Manufacturing of Phase 3 final Drug Product2SB1AI112097-08A1 · under PAR-20-129 | HENKEL, GREGORY WILLIAM | ARISAN THERAPEUTICS, INC., CA | $1,000,000 | ZRG1 |
| 2024 | Commercialization Readiness Pilot (CRP) program support for: Ultra-sensitive, direct-from-blood, molecular detection of Borrelia infections.1SB1AI183963-01 · under PAR-23-219 | SINGER, ALON | HELIXBIND, INC., MA | $1,000,000 | ZRG1 |
| 2024 | Whole Blood Point of Care Metabolic Measurement - SB11SB1HD116629-01 · under PAR-23-219 | THOMAS, MARYLAURA LIND | SEQUITUR HEALTH CORP., AZ | $1,000,000 | ZRG1 |
| 2024 | Scale-up manufacturing of microneedle stamp for peanut allergen immunotherapy1SB1AI184000-01 · under PAR-23-219 | PATEL, SAMIRKUMAR | MOONLIGHT THERAPEUTICS, INC., GA | $996,384 | ZRG1 |
| 2024 | Commercial and Regulatory Development of an Enhanced Performance Hemodialysis Access Graft1SB1HL174394-01 · under PAR-23-219 | MARSHALL, ANDREW | HEALIONICS CORPORATION, WA | $953,444 | ZRG1 |
| 2024 | Specificity Screening Drug Development Tool for Biotherapeutic Safety1SB1GM156044-01 · under PAR-23-219 | DORANZ, BENJAMIN J | INTEGRAL MOLECULAR, PA | $917,454 | ZRG1 |
| 2024 | Commercialization Readiness of Immune Mediator Based Blood Tests that Inform Concurrent and Future Clinical Disease Activity in Systemic Lupus Erythematosus (SLE)1SB1AI184309-01 · under PAR-23-219 | MUNROE, MELISSA E | PROGENTEC DIAGNOSTICS, INC., OK | $895,140 | ZRG1 |
| 2024 | A Novel Synthetically Engineered Oral Immunotherapy for Treating Ulcerative Colitis1SB1DK141356-01 · under PAR-23-219 | FANGER, GARYJANARDHANAN, SATHYANARAYANA | RISE THERAPEUTICS, LLC, MD | $673,379 | ZRG1 |
| 2024 | Late Stage Development of Sustained-release Relaxin for Treating Joint Contracture1SB1AR084380-01A1 · under PAR-23-219 | COOPER, BENJAMIN GOLDMAN | ORTHOLEVO, INC., MA | $504,965 | ZRG1 |
| 2024 | Definitive (GLP) Toxicity and Toxicology Studies for a Novel Small Molecule for Protection Against Cardiotoxicity in Triple Negative Breast Cancer1SB1HL174247-01 · under PAR-23-219 | SWINDLEHURST, CATHY A | NOVOMEDIX, INC., CA | $500,000 | ZRG1 |
| 2024 | Commercialization Readiness for Ductus Arteriosus Stent to Improve Congenital Heart Defect Mortality1SB1HL176266-01 · under PAR-23-219 | TANG, BEVERLY | STARLIGHT CARDIOVASCULAR, INC., CA | $500,000 | ZRG1 |
| 2024 | Portable Low-Cost Pulmonary Forced Oscillation Technique Device1SB1HL176360-01 · under PAR-23-219 | LICHTER, PATRICK | KORONIS BIOMEDICAL TECHNOLOGIES CORPORAT, MN | $499,966 | ZRG1 |
| 2024 | Design verification and validation of ViTrack - an accurate, continuous, non-invasive blood pressure monitor1SB1HL176287-01 · under PAR-23-219 | THANIKACHALAM, MOHAN | DYNOCARDIA, INC., MA | $499,881 | ZRG1 |
| 2024 | Advancing Commercial Readiness of a No-implant Interatrial Shunt Therapy to Treat Heart Failure1SB1HL174252-01 · under PAR-23-219 | PATE, THOMAS DIFFLEY | ALLEVIANT MEDICAL, INC., TX | $499,103 | ZRG1 |
| 2024 | Optimizing A Miniaturized and Integrated Continuous Glucose Monitoring Platform1SB1DK142387-01 · under PAR-23-219 | MUJEEB-U-RAHMAN, MUHAMMAD | INTEGRATED MEDICAL SENSORS, CA | $495,495 | ZRG1 |
| 2024 | Treatment and prevention of osteoarthritis with an intra-articular disease-modifying regenerative therapy1SB1AR084381-01 · under PAR-23-219 | ANGLE, SIDDHESH | REGENOSINE INC, NJ | $398,415 | ZRG1 |
| 2024 | Graphene-based Nanosensor Device for Rapid, Onsite Detection of Total Lead in Tap Water1SB1ES036493-01 · under PAR-23-219 | HILL, JAMES CURTIS | NANOAFFIX SCIENCE, LLC, WI | $300,000 | ZRG1 |
| 2024 | Novel Self-closing 12F Mitral Valve Repair System to Percutaneously Treat Moderate to Severe Regurgitation Using Transcatheter Edge-to-Edge Repair (TEER) Technique Via Femoral Vein Access.1SB1HL174244-01 · under PAR-23-219 | BASUDE, RAGHUVEER | MEDFREE, INC., CA | $275,530 | ZRG1 |
| 2024 | Leadless Pacemaker Betavoltaic Power Source1SB1HL174312-01A1 · under PAR-23-219 | CABAUY, PETER | CITY LABS, INC., FL | $251,156 | ZRG1 |
| 2024 | Advancing the commercialization readiness of nanoparticle-based immunotherapy for cancer treatment1SB1CA287735-01A1 · under PAR-23-219 | NGAMCHERDTRAKUL, WORAPOLYANTASEE, WASSANA | PDX PHARMACEUTICALS, INC., OR | $160,652 | ZRG1 |
| 2023 | Commercialization Readiness for Nerve Tape: a nerve repair coaptation aid1SB1NS137879-01A1 · under PAR-20-129 | CLEMENTS, ISAAC PERRY | BIOCIRCUIT TECHNOLOGIES, INC., GA | $1,887,020 | ZRG1 |
| 2023 | A Novel, Low-Cost Device to Guide Peripherally Inserted Central Catheter (PICC) Line Placement2SB1AG060793-04A1 · under PAR-20-129 | SHANAHAN, AUGUSTUS | PICCOLO MEDICAL, INC., CA | $1,702,062 | ZRG1 |
| 2023 | A State-of-the-Art Automatic Speech Recognition and Conversational Platform to Enable Socially Assistive Robots for Persons with Alzheimer's Disease and Related Dementias1SB1AG082634-01 · under PAR-20-129 | KERSSENS, CHANTAL M | CARE.COACH CORPORATION, CA | $1,298,083 | ZRG1 |
| 2023 | IND-enabling toxicology studies to reach IND approval for a proprietary biologic to treat oral mucositis in cancer patients2SB1DE024659-04A1 · under PAR-20-129 | WANG, XIAO-JINGYOUNG, CHRISTIAN | ALLANDER BIOTECHNOLOGIES, INC., CO | $1,239,748 | ZRG1 |
| 2023 | Antimicrobial dermal matrices to promote infection free wound closure in cutaneous wounds2SB1GM133305-04A1 · under PAR-20-129 | MEHTA, MANAV | GEL4MED, INC., MA | $1,200,000 | ZRG1 |
| 2023 | Framewise Integrated Real-Time MRI Monitoring (FIRMM) software commercialization readiness for clinical care1SB1MH133465-01 · under PAR-20-129 | BRUENER, KEN | TURING MEDICAL TECHNOLOGIES INC, MO | $1,062,778 | ZRG1 |
| 2023 | Therapy and Prophylaxis for Genital Tract Infection2SB1AI104067-07 · under PAR-20-129 | AUCI, DOMINICKRUSSELL, MICHAEL W | THERAPYX, INC., NY | $1,000,000 | ZRG1 |
| 2023 | Commercialization Readiness Pilot (CRP) program support for: Direct-from-specimen identification of pathogens common in endocarditis1SB1AI172440-01A1 · under PAR-20-129 | SINGER, ALON | HELIXBIND, INC., MA | $1,000,000 | ZRG1 |
| 2023 | Progressing PfSPZ vaccines for malaria to licensure and commercialization1SB1AI174403-01 · under PAR-20-129 | HOFFMAN, STEPHEN LEV | SANARIA, INC., MD | $999,921 | ZRG1 |
| 2023 | GMP manufacturing and IND Filing of IN-002, a potent inhaled muco-trapping antibody therapy for Respiratory Syncytial Virus1SB1AI179368-01 · under PAR-20-129 | HUTCHINS, JEFF T | INHALON BIOPHARMA, INC., NC | $999,810 | ZRG1 |
| 2023 | Therapeutic UV Disinfection System to Prevent Catheter Related Bloodstream Infections (CRBSIs) in Patients with Peripherally Inserted Central Catheters (PICCs)1SB1AI174371-01 · under PAR-20-129 | FOURKAS, MICHAELRASOOLY, JULIA | PURACATH MEDICAL, INC., CA | $999,306 | ZRG1 |
| 2023 | Custom Sensor Manufacturing and Regulatory Preparation Assistance for Novel Intraoperative Ureter Detection Device2SB1HD089769-04 · under PAR-20-129 | SHUKAIR, SHETHA | BRITESEED, LLC, IL | $497,923 | ZRG1 |
| 2023 | DermiSphere™: An Advanced Dermal Regeneration Scaffold for Reconstructive Surgery, CRP2SB1AR076301-04 · under PAR-20-129 | SAPIR LEKHOVITSER, YULIA | FESARIUSTHERAPEUTICS, INC., NY | $399,734 | ZRG1 |
| 2023 | IND-enabling studies of an intranasal, single-replication M2SR influenza vaccine2SB1AI120269-04A1 · under PAR-20-129 | BILSEL, PAMUK | FLUGEN, INC., WI | $349,605 | ZRG1 |
| 2023 | Novel Guidewire Design and Coating for Adenosine Delivery2SB1HL136233-03 · under PAR-20-129 | FORMAN, MERVYN B. | ADENOPAINT, LLC, GA | $249,999 | ZRG1 |
| 2023 | Minimally invasive access and aspiration of circulating lymphocytes from the thoracic duct2SB1DK109876-04A1 · under PAR-20-129 | CALLAGHAN, MATTHEW | LXS, INC., CA | $1 | ZRG1 |
| 2022 | Commercialization of ALM-488 for Highlighting Nerves During Image Guided Surgeries1SB1NS127647-01 · under PAR-20-129 | BERMAN, BRETT J.WHITNEY, MICHAEL A | ALUME BIOSCIENCES, INC., CA | $1,670,941 | ZRG1 |
| 2022 | Commercialization readiness of visual biofeedback to reduce head motion during MRI scans1SB1MH126825-01A1 · under PAR-20-129 | BRUENER, KENDECKARD, TODD WILLIAM | TURING MEDICAL TECHNOLOGIES INC, MO | $1,136,868 | ZRG1 |
| 2022 | Thermal Imaging Modality for Detection of Large and Small Fiber Diabetic Peripheral Neuropathy1SB1DK135209-01 · under PAR-20-129 | SOLIZ, PETER N | VISIONQUEST BIOMEDICAL INC, NM | $1,001,136 | ZRG1 |
| 2022 | Commercialization Readiness Pilot (CRP) program support for: An Integrated Device for identification of bloodstream infections directly from blood1SB1AI172427-01 · under PAR-20-129 | SINGER, ALON | HELIXBIND, INC., MA | $1,000,000 | ZRG1 |
| 2022 | Long Lasting Organic Semiochemical Formulation to Effectively Manage Blood Sucking Diptera.2SB1AI134144-04A1 · under PAR-20-129 | MAFRA-NETO, AGENOR | ISCA TECHNOLOGIES, INC., CA | $1,000,000 | ZRG1 |
| 2022 | Commercialization of PANDAA qDx for rapid drug resistance genotyping of protease inhibitor ART failures in resource-limited settings.2SB1AI128974-04 · under PAR-20-129 | MACLEOD, IAIN JAMES | ALDATU BIOSCIENCES, INC., MA | $992,797 | ZRG1 |
| 2022 | Development of DYRK1A allosteric modulator for the treatment of Alzheimer's Disease2SB1AG056181-04 · under PAR-20-129 | ARALDI, GIAN LUCA | AVANTI BIOSCIENCES, INC., NY | $976,999 | ZRG1 |
| 2022 | Commercialization of Low-Cost Portable 3D Ultrasound for Surveillance of Arteriovenous Fistula Maturation by Point-of-Care Dialysis Clinicians2SB1HL147423-07A1 · under PAR-20-129 | KANG, XIN | SONAVEX, INC., MD | $500,000 | ZRG1 |
| 2022 | Transdermal H2S Sensing Device for Monitoring Peripheral Artery Disease2SB1HL121871-04 · under PAR-20-129 | SHEKARRIZ, REZA | EXHALIX, LLC, NM | $500,000 | ZRG1 |
| 2022 | Commercialization readiness for a 3D image guidance system to support interventional procedures in the spine and pelvis1SB1AR082178-01 · under PAR-20-129 | MAULDIN, FRANK WILLIAM | RIVANNA MEDICAL, INC., VA | $403,074 | ZRG1 |
| 2022 | Unicondylar Resurfacing in an Ovine Osteoarthritis Disease Model2SB1AR066439-04A1 · under PAR-20-129 | ESTES, BRADLEY T | CYTEX THERAPEUTICS INC., NC | $400,000 | ZRG1 |
| 2022 | MVT-100 Manufacturing and Commercialization.2SB1HL137447-03A1 · under PAR-20-129 | UNGER, WYATT DANIEL | MICROVASCULAR THERAPEUTICS, LLC, AZ | $292,149 | ZRG1 |
| 2021 | Glycosaminoglycans to Treat and Prevent Radiation-Induced Oral Mucositis2SB1DE024024-04 · under PAR-20-129 | LEE, WON YONG | GLYCOMIRA, LLC, UT | $1,530,893 | ZRG1 |
| 2021 | Commercialization, Adoption, Licensing and Manufacture of Exersides Refraints1SB1AG073026-01 · under PAR-20-129 | PAVINI, MARIE | HEALTHY DESIGN, LTD. CO., VT | $1,490,227 | ZRG1 |
| 2021 | Commercialization of Safe and Effective Locoregional Head and Neck Cancer Therapy2R44DE023725-04 · under PAR-19-333 | GOLDBERG, MANIJEH NKEITH, DONNA | PRIVO TECHNOLOGIES, LLC, MA | $1,183,038 | ZRG1 |
| 2021 | Microarray Patch for Broadly Protective Seasonal Influenza Vaccination1SB1AI164584-01 · under PAR-19-333 | KOSUDA, KATHRYN | VAXESS TECHNOLOGIES, INC., MA | $1,000,000 | ZRG1 |
| 2021 | Next-generation phenotypic antimicrobial susceptibility test platform: rapid resultsand comprehensive menus2SB1AI136125-04A1 · under PAR-20-129 | STERN, ERIC | SELUX DIAGNOSTICS, INC., MA | $999,992 | ZRG1 |
| 2021 | Malarial retinopathy screening system for improved diagnosis of cerebral malaria1SB1AI162452-01 · under PAR-20-129 | JOSHI, VINAYAK S | VISIONQUEST BIOMEDICAL INC, NM | $999,158 | ZRG1 |
| 2021 | A Novel Probiotic for the Treatment of Sjogren's Syndrome1SB1DE030833-01A1 · under PAR-20-129 | FANGER, GARY | RISE THERAPEUTICS, LLC, MD | $998,658 | ZRG1 |
| 2021 | PreQuine Platform. A novel point of care device for the diagnosis andmonitoring of Glucose-6-Phosphate Dehydrogenase (G6PD)2SB1AI129057-04 · under PAR-20-129 | HARPER, ROBERT | ANALYTICAL DIAGNOSTIC SOLUTIONS, INC., NJ | $990,200 | ZRG1 |
| 2021 | A preclinical multi-modal system for dynamic noninvasive assessment of liver disease2SB1DK112492-04A1 · under PAR-20-129 | CZERNUSZEWICZ, TOMASZ JOSEPH | SONOVOL, INC., NC | $989,080 | ZRG1 |
| 2021 | Commercialization Readiness for Bone Filler Scaffold Device to Aid in Dental Applications and Reconstruction2SB1DE028213-04 · under PAR-20-129 | ALGHAZALI, KARRERBALLARD, SHARON C | NUSHORES BIOSCIENCES, LLC, AR | $977,882 | ZRG1 |
| 2021 | An Innovative Person-Centered Hearing Aid Education and Aural Rehab System2R44AG045947-04A1 · under PAR-19-333 | LETZT, ALAN | HEALTHCARE TECHNOLOGIES AND METHODS, VA | $936,620 | ZRG1 |
| 2021 | Novel peptide-impregnated hydrogel as a wound healing device2R44DE026080-03 · under PAR-19-333 | TING, KANGZHENG, ZHONG | SCARLESS LABORATORIES, INC., CA | $902,470 | ZRG1 |
| 2021 | Portable Hearing Laboratory - CRP2R44DC016247-05 · under PAR-19-333 | PAVLOVIC, CASLAV VOJISLAV | BATANDCAT, INC., CA | $837,653 | ZRG1 |
| 2021 | Active Disposable Cap for Endoscope Tip Stabilization and Complete Visualization and Dissection of Serrated Sessile Polyps2SB1DK117813-04A1 · under PAR-20-129 | MULVIHILL, MAUREEN L. | ACTUATED MEDICAL, INC., PA | $694,543 | ZRG1 |
| 2021 | Sutra TMVR delivery system development and V&V testing2SB1HL140835-04A1 · under PAR-20-129 | PHAM, THUY M | SUTRA MEDICAL, INC., CA | $500,000 | ZRG1 |
| 2021 | Manufacturing Scale-up, Purification, and Analytical Method Development, Validation and Qualification for KC1003, Key Precursor for ErythroMer (RBC substitute)2SB1HL135965-04 · under PAR-20-129 | ALP, ESMA | KALOCYTE, INC., MD | $499,999 | ZRG1 |
| 2021 | Image-Guided Transurethral HIFU for Genitourinary Therapy2SB1DK108458-03A1 · under PAR-20-129 | BURDETTE, EVERETTE CDIEDERICH, CHRIS JOHN | ACOUSTIC MEDSYSTEMS, INC., IL | $479,133 | ZRG1 |
| 2021 | Ultrathin dissolvable antibiofilm wound contact dressing with silver and gallium1SB1AR079347-01 · under PAR-20-129 | AGARWAL, ANKIT | IMBED BIOSCIENCES, INC., WI | $405,056 | ZRG1 |
| 2021 | Commercial readiness of Break Wave - The SonoMotion Office-Based Lithotripsy Solution1SB1DK131760-01 · under PAR-20-129 | LEVY, OREN | SONOMOTION, INC., CA | $399,954 | ZRG1 |
| 2020 | Advancing SRX246 to Commericialization2R44NS090616-05 · under PAR-19-333 | BROWNSTEIN, MICHAEL J | AZEVAN PHARMACEUTICALS, INC., PA | $3,190,881 | ZRG1 |
| 2020 | Commercialization Readiness Program (CRP) for Bioabsorbable Magnesium (Mg) Implants for Craniomaxillofacial Surgical Systems2R44DE024919-04 · under PAR-19-333 | LEBEAU, STEPHEN | NANOMAG, LLC, MI | $2,260,835 | ZRG1 |
| 2020 | IND-Enabling Pre-clinical Development of Modified P8 for the Treatment of Alzheimer's Disease2R44AG043278-06A1 · under PAR-19-333 | DEWJI, NAZNEEN N | CENNA BIOSCIENCES, INC., CA | $1,750,000 | ZRG1 |
| 2020 | Commercialization Readiness Pilot (CRP) to maximize vamorolone international labeling and sales2SB1NS095423-05A1 · under PAR-19-333 | HOFFMAN, ERIC P. | REVERAGEN BIOPHARMA, INC., MD | $1,680,179 | ZRG1 |
| 2020 | Commercialization Readiness Pilot for Amplifying Fibrinolysis in Ischemic Stroke2R44NS073147-05 · under PAR-19-333 | REED, GUY LWANG, DONG | TRANSLATIONAL SCIENCES, INC., AZ | $1,646,140 | ZRG1 |
| 2020 | Development and Commercialization of a Tau Oligomer Inhibitor for AD/RD2R44AG053150-05 · under PAR-19-333 | MOE, JAMES G. | OLIGOMERIX, INC, NY | $1,452,237 | ZRG1 |
| 2020 | Brain-enriched microRNAs detectable in plasma as biomarkers of Alzheimer's Disease2R44AG044860-07 · under PAR-19-333 | UMANSKY, SAMUIL R | DIAMIR, LLC, NJ | $1,250,063 | ZRG1 |
| 2020 | PfSPZ Vaccine for Malaria: Towards a Successful Biologics License Application and Commercialization2SB1AI058375-12 · under PAR-19-333 | HOFFMAN, STEPHEN LEV | SANARIA, INC., MD | $998,833 | ZRG1 |
| 2020 | Wearable Nanoelectronic Vapor Sensors for Transdermal Alcohol Monitoring2R44AA026119-04 · under PAR-19-333 | KULKARNI, GIRISH | ARBORSENSE, INC., MI | $566,692 | ZRG1 |
| 2020 | Final Development and Testing of Patient Breath Simulator/Capnometer Test Device2R44HL124699-03 · under PAR-19-333 | ZITTING, DARRYL | WITTING INNOVATION, LLC, UT | $499,400 | ZRG1 |
| 2020 | Enhancing the Commercialization Readiness of a Noninvasive Total Hemoglobin Monitor2SB1HL106860-04 · under PAR-19-333 | POLOGE, JONAS ALEXANDER | KESTREL LABS, INC., CO | $329,470 | ZRG1 |
| 2020 | Improving Anticoagulation Monitoring in Pediatric Patients: Use of a Microfluidic Platform to Test Low Volume Blood Samples Obtained by Heel-Stick Collection2R44HL140662-04 · under PAR-19-333 | PAMULA, VAMSEE K. | BAEBIES, INC., NC | $214,063 | ZRG1 |
| 2018 | Portable Device for Telecare Monitoring of Elderly People2SB1AG032748-06 · under PAR-16-027 | GWIN, JOSEPH T | BIOSENSICS, LLC, MA | $1,000,000 | ZRG1 |
| 2018 | Late stage development and preparation of a long-term non-enzymatic continuous glucose sensor for clinical trials2SB1DK101000-04 · under PAR-16-027 | GAMSEY, SOYAREBRIN, KERSTIN | PROFUSA, INC., CA | $605,501 | ZRG1 |
| 2017 | MR191_ An Immunoprotectant for Marburg Virus2SB1AI082744-06A1 · under PAR-16-027 | AIMES, RONALD T | MAPP BIOPHARMACEUTICAL, INC., CA | $1,000,000 | ZRG1 |
| 2017 | Therapeutic D-peptide Inhibitor of HIV Entry2SB1AI095172-05 · under PAR-16-027 | MUELLER, ALAN LWETTSTEIN, DANIEL A | NAVIGEN, INC., UT | $1,000,000 | ZRG1 |
| 2017 | Therapeutic Antibodies for Biofilm Infections2SB1AI120425-03 · under PAR-16-027 | KAUVAR, LAWRENCE MICHAEL | TRELLIS BIOSCIENCE, INC., CA | $999,953 | ZRG1 |
| 2017 | Therapeutic Antibody for CMV2SB1AI102396-06 · under PAR-16-027 | KAUVAR, LAWRENCE MICHAEL | TRELLIS BIOSCIENCE, INC., CA | $999,000 | ZRG1 |
| 2017 | Marketing Strategic Plan and Distribution Logistics for Sanaria PfSPZ Vaccine against Malaria.2SB1AI077262-06 · under PAR-16-027 | HOFFMAN, STEPHEN LEV | SANARIA, INC., MD | $996,292 | ZRG1 |
| 2017 | Assessment of chronic toxicity to support the use of topical pirenzepine for treating diabetic neuropathy2SB1DK104512-04 · under PAR-16-027 | HANSEN, ANGELA | WINSANTOR, INC., CA | $970,226 | ZRG1 |
| 2017 | Anti-scar peptide for cleft lip repair2SB1DE026972-04A1 · under PAR-16-027 | SOO, CHIAZHENG, ZHONG | SCARLESS LABORATORIES, INC., CA | $968,061 | ZRG1 |
| 2017 | IMMEDIATE FIT USING INNOVATIVE TECHNOLOGY PROSTHETIC SYSTEMS2SB1AG050430-06 · under PAR-16-027 | DILLINGHAM, TIMOTHY R | IFIT PROSTHETICS, LLC, WI | $954,824 | ZRG1 |
| 2017 | Commercial Readiness for SAMBA HIV-1 Whole Blood Semi-Quantitative Test for Resource Limited Settings2SB1AI097120-05A1 · under PAR-16-027 | LEE, HELEN H | DIAGNOSTICS FOR THE REAL WORLD, LTD, CA | $907,877 | ZRG1 |
| 2017 | Evaluation of a Novel Connexin-Based Peptide for the Treatment of Diabetic Wounds2SB1DK080567-07 · under PAR-16-027 | GHATNEKAR, GAUTAM SUDHIR | XEQUEL BIO, INC., SC | $852,751 | ZRG1 |
| 2017 | CAMCI: Advancing the Use of Computerized Screening in Healthcare2SB1AG037357-04A1 · under PAR-16-027 | ESCHMAN, AMY | PSYCHOLOGY SOFTWARE TOOLS, INC., PA | $836,212 | ZRG1 |
| 2017 | Peripheral nerve stimulation for amputee pain2SB1NS066523-05 · under PAR-16-027 | BOGGS, JOSEPH WILDER | SPR THERAPEUTICS, LLC, OH | $813,769 | ZRG1 |
| 2017 | A Novel Small Molecule TNF-alpha Inhibitor as a Disease-Modifying Alzheimer's Disease Drug Treatment2SB1AG051302-04 · under PAR-16-027 | GABBITA, SOMASUNDAR PRASAD | P2D, INC., OH | $696,900 | ZRG1 |
| 2017 | Commercialization of TrueContour® Custom Diabetic Foot Orthoses2SB1DK059074-08A1 · under PAR-16-027 | CAVANAGH, PETER ROBERT | DIAPEDIA, LLC, PA | $621,123 | ZRG1 |
| 2017 | Clinical Development of Tacrolimus for Hemorrhagic Cystitis2SB1DK102247-04A1 · under PAR-16-027 | KAUFMAN, JONATHAN H | LIPELLA PHARMACEUTICALS, INC., PA | $514,245 | ZRG1 |
| 2017 | Manufacturable and reliable electrically pumped micro-electromechanically tunable vertical cavity surface emitting lasers for low-cost ophthalmic swept source optical coherence tomography2SB1EY022864-04 · under PAR-16-027 | BURGNER, CHRISTOPHER | PRAEVIUM RESEARCH, INC., CA | $500,000 | ZRG1 |
| 2017 | Micro Patterned Intraocular Lens Membrane for Reducing Incidence of PCO2SB1EY022541-04 · under PAR-16-027 | CUEVAS, KEVINREDDY, SHRAVANTHI | CLEARSIGHT, LLC, CO | $499,999 | ZRG1 |
| 2017 | De-risking ONL1204 to enable venture capital investment for first-in-human clinical trials2SB1EY022512-03 · under PAR-16-027 | VAN DE GOOR, JANA | ONL THERAPEUTICS, INC., MI | $499,761 | ZRG1 |
| 2017 | Microtechnology-Enhanced Pediatric & Adult Lens Capsulotomy Device2SB1EY021023-06 · under PAR-16-027 | HENDRICK, JOHN N | MYNOSYS CELLULAR DEVICES, INC., CA | $499,690 | ZRG1 |
| 2017 | Commercial readiness of kidney stone repositioning – The SonoMotion solution2SB1DK107094-04 · under PAR-16-027 | LEVY, OREN | SONOMOTION, INC., CA | $470,748 | ZRG1 |
| 2017 | Fracture Risk Assessment Software for Skeletal Metastasis2SB1AR069421-02 · under PAR-16-027 | GWIN, JOSEPH T | BIOSENSICS, LLC, MA | $400,000 | ZRG1 |
| 2017 | A crosslinked cartilage-derived matrix for cartilage tissue engineering2SB1AR061916-04 · under PAR-16-027 | MOUTOS, FRANK | CYTEX THERAPEUTICS INC., NC | $400,000 | ZRG1 |
| 2017 | Modulated Imaging: Toward commercialization of a wide-field optical imaging platform for wound care2SB1AR064657-06A1 · under PAR-16-027 | CUCCIA, DAVID JMAZHAR, AMAAN | MODULATED IMAGING, INC., CA | $399,976 | ZRG1 |
| 2016 | Development of a Biochemical Diagnosis for Creutzfeldt-Jakob disease2SB1NS079060-04 · under PAR-16-027 | LEBOVITZ, RUSSELL MSOTO, CLAUDIO | AMPRION, INC., CA | $1,254,529 | ZRG1 |
| 2016 | Rapid Identification of Pathogenic Bacteria in Blood causing Sepsis2SB1AI094781-04 · under PAR-16-027 | MARTINO, RAY ANTHONY | ISENSE, LLC, FL | $998,515 | ZRG1 |
| 2016 | PfSPZ Vaccines: Quality Systems, Manufacturing, Regulatory, and Clinical Quality and Data Management Support for Product Commercialization2SB1AI055229-12 · under PAR-16-027 | HOFFMAN, STEPHEN LEV | SANARIA, INC., MD | $991,532 | ZRG1 |
| 2016 | High-quality compact portable low-field head MRI with ultra-fast gradients2SB1NS073289-09 · under PAR-16-027 | WEINBERG, IRVING | WEINBERG MEDICAL PHYSICS, LLC, MD | $989,683 | ZRG1 |
| 2016 | Near patient molecular diagnostics test for infections2SB1AI088756-06 · under PAR-16-027 | GAU, VINCENT JEN-JR | GENEFLUIDICS, INC., CA | $989,569 | ZRG1 |
| 2016 | Human Apyrase Therapy for Acute Ischemic Stroke2SB1NS060175-04 · under PAR-16-027 | CHEN, RIDONG | APT THERAPEUTICS, INC., IL | $968,157 | ZRG1 |
| 2016 | Advanced Bicycle Helmet Technology for Prevention of Traumatic Brain Injury2SB1NS074734-04 · under PAR-16-027 | BOTTLANG, MICHAEL | APEX BIOMEDICAL COMPANY, LLC, OR | $617,779 | ZRG1 |
| 2016 | Vaginal Tactile Imager for Pelvic Floor Biomechanical Assessment2SB1AG034714-06 · under PAR-16-027 | SARVAZYAN, NOUNE | ARTANN LABORATORIES, INC., NJ | $575,753 | ZRG1 |
| 2016 | Computer-based Screening for Diabetic Retinopathy2SB1EY018280-06 · under PAR-16-027 | SOLIZ, PETER N | VISIONQUEST BIOMEDICAL, LLC, NM | $499,791 | ZRG1 |
| 2016 | An Internet Application for SMART Recovery2SB1AA016237-05 · under PAR-16-027 | HESTER, REID KEVIN | CHECKUP AND CHOICES, LLC, NM | $263,179 | ZRG1 |
| 2016 | Hip-Joint Resurfacing with Functional Human Cartilage2SB1AR055414-04 · under PAR-16-027 | ESTES, BRADLEY T | CYTEX THERAPEUTICS INC., NC | $187,590 | ZRG1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.